Genomics, heart failure and sudden cardiac death

Heart Failure Reviews

Volumn 15, Issue 3, 2010, Pages 229-238

  Darbar, Dawood ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genomics; Heart failure; Single nucleotide polymorphisms; Sudden cardiac death

Indexed keywords

ALDOSTERONE SYNTHASE; ALPHA 2 ADRENERGIC RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BISOPROLOL; CALCIUM; CARVEDILOL; CONNEXIN 43; DELAYED RECTIFIER POTASSIUM CHANNEL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL SUCCINATE; PHOSPHOLAMBAN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RYANODINE RECEPTOR 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL NAV1.5; STROMELYSIN; ADRENERGIC RECEPTOR;

ATHEROSCLEROSIS; CALCIUM HOMEOSTASIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEFIBRILLATOR; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOMICS; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; INDEL MUTATION; LONG QT SYNDROME; NONHUMAN; PREDICTION; PRIMARY PREVENTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SUDDEN DEATH; THROMBOSIS; TORSADE DES POINTES; CELL COMMUNICATION; CHROMOSOME MAP; GENETICS; METABOLISM; PHARMACOGENETICS; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ARRHYTHMIAS, CARDIAC; ATHEROSCLEROSIS; CALCIUM; CELL COMMUNICATION; CHROMOSOME MAPPING; DEATH, SUDDEN, CARDIAC; HEART FAILURE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; RISK FACTORS;

EID: 77954630967     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-008-9095-9     Document Type: Review

References (70)

1. Association AH (2006) Heart disease and stroke statistics - 2006 update. American Heart Association, Dallas, TX
2. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D (1993) Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation 88:107-115
3. Goldman S, Johnson G, Cohn JN, Cintron G, Smith R, Francis G (1993) Mechanism of death in heart failure. The vasodilator-heart failure trials. The V-HeFT VA cooperative studies group. Circulation 87:VI24-VI31
4. Narang R, Cleland JG, Erhardt L et al (1996) Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 17:1390-1403
5. Kannel WB, Plehn JF, Cupples LA (1988) Cardiac failure and sudden death in the Framingham study. Am Heart J 115:869-875
6. Moss AJ, Hall WJ, Cannom DS et al (1996) Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med 335: 1933-1940
7. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G (1999) A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators. N Engl J Med 341: 1882-1890
8. Moss AJ, Zareba W, Hall WJ et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877-883
9. Bardy GH, Lee KL, Mark DB et al (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225-237
10. Josephson M, Wellens HJ (2004) Implantable defibrillators and sudden cardiac death. Circulation 109:2685-2691
11. Zipes DP, Wellens HJ (1998) Sudden cardiac death. Circulation 98:2334-2351
12. Yang P, Kanki H, Drolet B et al (2002) Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105:1943-1948
13. Roden DM (1998) Taking the "idio" out of " idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 21:1029-1034
14. Splawski I, Timothy KW, Tateyama M et al (2002) Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 297:1333-1336
15. Schwartz PJ, Vanoli E, Stramba-Badiale M, De Ferrari GM, Billman GE, Foreman RD (1988) Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. Circulation 78:969-979
16. Tomaselli GF, Zipes DP (2004) What causes sudden death in heart failure? Circ Res 95:754-763
17. Chen PS, Chen LS, Cao JM, Sharifi B, Karagueuzian HS, Fishbein MC (2001) Sympathetic nerve sprouting, electrical remodeling and the mechanisms of sudden cardiac death. Cardiovasc Res 50:409-416
18. Small KM, McGraw DW, Liggett SB (2003) Pharmacology and physiology of human adrenergic receptor polymorphisms. Ann Rev Pharmacol Toxicol 43:381-411 Epub 2002 Jan 10
19. Liggett SB (2004) Genetically modified mouse models for pharmacogenomic research. Nat Rev Genet 5:657-663
20. Drummond GA, Squire IB (1999) The cardiac insufficiency bisoprolol study II. Lancet 353:1361
21. Merit-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353: 2001-2007
22. Packer M, Bristow MR, Cohn JN et al (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US carvedilol heart failure study group. N Engl J Med 334:1349-1355
23. Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y (2002) The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 277:30429-30435
24. Ranade K, Jorgenson E, Sheu WH et al (2002) A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet 70:935-942
25. Borjesson M, Magnusson Y, Hjalmarson A, Andersson B (2000) A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 21:1853-1858
26. Mason DA, Moore JD, Green SA, Liggett SB (1999) A gain-offunction polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 274:12670-12674
27. Liggett SB, Mialet-Perez J, Thaneemit-Chen S et al (2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 103:11288-11293
28. Green SA, Cole G, Jacinto M, Innis M, Liggett SB (1993) A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 268:23116-23121
29. Green SA, Turki J, Innis M, Liggett SB (1994) Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33:9414-9419
30. Sotoodehnia N, Siscovick DS, Vatta M et al (2006) Beta2-adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation 113:1842-1848
31. Liggett SB (2006) Beta2-adrenergic receptor polymorphisms and sudden cardiac death: a signal to follow. Circulation 113:1818-1820
32. Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341:709-717
33. Sleight P (2002) Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol 89:11A-16A; discussion 16A-17A
34. Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA (1999) Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 33:598-604
35. Seidman JG, Seidman C (2001) The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104:557-567
36. Takeishi Y, Walsh RA (2001) Cardiac hypertrophy and failure: lessons learned from genetically engineered mice. Acta Physiol Scand 173:103-111
37. Lim DS, Lutucuta S, Bachireddy P et al (2001) Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103:789-791
38. Samani NJ, Thompson JR, O'Toole L, Channer K, Woods KL (1996) A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 94:708-712 (Pubitemid 26289226)
39. Raynolds MV, Bristow MR, Bush EW et al (1993) Angiotensinconverting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 342:1073-1075
40. Marian AJ, Yu QT, Workman R, Greve G, Roberts R (1993) Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 342:1085-1086
41. Bedi MS, Postava LA, Murali S et al (2004) Interaction of implantable defibrillator therapy with angiotensin-converting enzyme deletion/insertion polymorphism. J Cardiovasc Electrophysiol 15:1162-1166
42. Pacifico A, Henry PD (2003) Structural pathways and prevention of heart failure and sudden death. J Cardiovasc Electrophysiol 14:764-775
43. Kanno S, Saffitz JE (2001) The role of myocardial gap junctions in electrical conduction and arrhythmogenesis. Cardiovasc Pathol 10:169-177
44. Spach MS, Josephson ME (1994) Initiating reentry: the role of nonuniform anisotropy in small circuits. J Cardiovasc Electrophysiol 5:182-209
45. Lerner DL, Yamada KA, Schuessler RB, Saffitz JE (2000) Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation 101:547-552
46. Gutstein DE, Morley GE, Tamaddon H et al (2001) Conduction slowing and sudden arrhythmic death in mice with cardiacrestricted inactivation of connexin43. Circ Res 88:333-339
47. Yao JA, Gutstein DE, Liu F, Fishman GI, Wit AL (2003) Cell coupling between ventricular myocyte pairs from connexin43-deficient murine hearts. Circ Res 93:736-743
48. Thompson CA, Yarzebski J, Goldberg RJ, Lessard D, Gore JM, Dalen JE (2000) Changes over time in the incidence and casefatality rates of primary ventricular fibrillation complicating acute myocardial infarction: perspectives from the Worcester heart attack study. Am Heart J 139:1014-1021
49. Dekker LR, Bezzina CR, Henriques JP et al (2006) Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation 114:1140-1145
50. Gnasso A, Motti C, Irace C et al (2000) Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol 20: 1600-1605
51. Weiss EJ, Bray PF, Tayback M et al (1996) A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 334:1090-1094
52. Mikkelsson J, Perola M, Laippala P, Penttila A, Karhunen PJ (2000) Glycoprotein IIIa Pl(A1/A2) polymorphism and sudden cardiac death. J Am Coll Cardiol 36:1317-1323
53. Snapir A, Mikkelsson J, Perola M, Penttila A, Scheinin M, Karhunen PJ (2003) Variation in the alpha2B-adrenoceptor gene as a risk factor for prehospital fatal myocardial infarction and sudden cardiac death. J Am Coll Cardiol 41:190-194
54. Anvari A, Schuster E, Gottsauner-Wolf M, Wojta J, Huber K (2001) PAI-I 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease. Thromb Res 103:103-107
55. Iwai N, Shimoike H, Nakamura Y, Tamaki S, Kinoshita M (1998) The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis 136:109-114
56. Wang XL, Sim AS, Wang MX, Murrell GA, Trudinger B, Wang J (2000) Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. FEBS Lett 471:45-50
57. Nakayama M, Yasue H, Yoshimura M et al (1999) T-786 - >C mutation in the 50-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99:2864-2870
58. Bers DM (2002) Cardiac excitation-contraction coupling. Nature 415:198-205
59. Priori SG, Napolitano C, Tiso N et al (2001) Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103:196-200 (Pubitemid 32095402)
60. Terentyev D, Viatchenko-Karpinski S, Gyorke I, Volpe P, Williams SC, Gyorke S (2003) Calsequestrin determines the functional size and stability of cardiac intracellular calcium stores: mechanism for hereditary arrhythmia. Proc Natl Acad Sci USA 100:11759-11764
61. Lahat H, Pras E, Olender T et al (2001) A missense mutation in a highly conserved region of CASQ2 is associated with autosomalrecessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 69: 1378-1384
62. Splawski I, Timothy KW, Sharpe LM et al (2004) Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119:19-31
63. Splawski I, Timothy KW, Decher N et al (2005) Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci USA 102:8089-8096
64. MacLennan DH, Asahi M, Tupling AR (2003) The regulation of SERCA-type pumps by phospholamban and sarcolipin. Ann N Y Acad Sci 986:472-480
65. Ozaki K, Ohnishi Y, Iida A et al (2002) Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 32:650-654
66. Samani NJ, Erdmann J, Hall AS et al (2007) Genomewide association analysis of coronary artery disease. N Engl J Med 357:443-453 (Pubitemid 47204873)
67. Gudbjartsson DF, Arnar DO, Helgadottir A et al (2007) Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 448(7151):353-357
68. Arking DE, Pfeufer A, Post W et al (2006) A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet 38:644-651
69. Newton-Cheh C, Larson MG, Corey DC et al (2005) QT interval is a heritable quantitative trait with evidence of linkage to chromosome 3 in a genome-wide linkage analysis: the Framingham heart study. Heart Rhythm 2:277-284
70. Baum AE, Akula N, Cabanero M et al (2008) A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 13:197-207